Viking Therapeutics has reached a significant achievement in its clinical development program, announcing the early completion of patient enrollment for its pivotal Phase 3 VANQUISH-1 trial. The study, which will support regulatory approval for the company’s obesity treatment candidate VK2735, exceeded its recruitment targets amid substantial patient interest.
Accelerated Trial Progress with Expanded Participation
The biotechnology firm confirmed that enrollment concluded ahead of schedule with approximately 4,650 adult participants, surpassing the trial’s original recruitment goals. This robust enrollment figure underscores both the substantial demand for innovative obesity therapies and Viking’s operational effectiveness in executing clinical programs.
VANQUISH-1 represents a randomized, double-blind, placebo-controlled investigation evaluating VK2735, a dual GLP-1/GIP receptor agonist. The study’s primary focus centers on measuring weight change percentage following a 78-week treatment period. The accelerated enrollment timeline suggests strong patient enthusiasm for new therapeutic options in the metabolic disease space.
Financial Strength Supports Clinical Advancement
During a recent presentation at the Jefferies London Healthcare Conference, company management highlighted Viking’s substantial financial resources. With cash reserves exceeding $700 million, the organization maintains full funding through the critical data readouts from its Phase 3 clinical trials.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Beyond the injectable formulation currently in Phase 3 testing, Viking continues to advance an oral version of VK2735 through Phase 2 evaluation. Previous clinical investigations have demonstrated promising efficacy, with study participants achieving average weight reduction of up to 14.7% after just 13 weeks of treatment.
Upcoming Development Milestones
Several important catalysts await Viking Therapeutics in the coming quarters. Topline results from the VANQUISH-1 study are anticipated following completion of the 78-week treatment period. Concurrently, patient recruitment continues for VANQUISH-2, a second Phase 3 trial examining VK2735 in diabetic patients with obesity, with completion targeted for the first quarter of 2026.
The company has scheduled an upcoming meeting with the U.S. Food and Drug Administration regarding the oral formulation of VK2735. Additionally, Viking plans to submit an Investigational New Drug application for its amylin agonist program during 2026. Market observers position the company as an important independent contender within the valuable obesity treatment market.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from November 20 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 20.
Viking Therapeutics: Buy or sell? Read more here...
